Effect of SGLT2 Inhibitors on Anemic CKD Patients

Starting soon

Conditions studied: Anemia in CKD Patients

In brief

anemia is a common complication of CKD patients and affect the quality of life and increase morbidity and mortality. managing anemia in CKD patients remains challenging conventional therapy including iron and ESAs which has its complications. the SGLT2 inhibitors have emerging evidence from major clinical trials in improving anemia in patients with CKD

Key facts

Study ID

NCT07334145

Run by

Sohag University

People needed

60

Starts

2026-01-01

Expected to finish

2026-09-01

Last updated by the study team

2026-01-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• age more than 18 years
• CKD stage 1_4
• baseline hemoglobin 8.5 to 12.9 g/dl
• stable anemia regimen for more than 8 weeks

You may not qualify if…

• dialysis recent blood transfusion or ESA dose change within 8 weeks active malignancy or infection pregnancy or lactation history of recurrent DKA or sever volume depletion

Where it is running

• Sohag University Hospital — Sohag, Sohag University, Egypt

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.